# Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

> **NCT01389427** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 41 (actual)

## Conditions studied

- Mantle Cell Lymphoma Refractory

## Interventions

- **DRUG:** Torisel dose 15 mg and R-CHOP
- **DRUG:** Torisel dose 15 mg and R-FC
- **DRUG:** Torisel dose 15 mg and R-DHA
- **DRUG:** Torisel dose 25 mg and R-CHOP
- **DRUG:** Torisel dose 50 mg and R-CHOP
- **DRUG:** Torisel dose 75 mg and R-CHOP
- **DRUG:** Torisel dose 25 mg and R-FC
- **DRUG:** Torisel dose 50 mg and R-FC
- **DRUG:** Torisel dose 75 mg and R-FC
- **DRUG:** Torisel dose 25 mg and R-DHA
- **DRUG:** Torisel dose 50 mg and R-DHA
- **DRUG:** Torisel 75 mg and R-DHA

## Key facts

- **NCT ID:** NCT01389427
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389427, "Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01389427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*